News

Medical Dialogues14h
Itepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...
MedPage Today2h
ADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast Cancer
As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...